JPMorgan raised the firm’s price target on Cogent Biosciences (COGT) to $21 from $19 and keeps an Overweight rating on the shares. The firm says its physician survey data suggests enthusiasm for the potential of bezuclastinib in advanced systemic mastocytosis and non-advanced. The firm believes safety concerns for the program are overblown and that bezuclastinib has the potential to “navigate a clean therapeutic window across indications.” It sees “plenty of upside” in Cogent shares on only the advanced systemic mastocytosis and gastrointestinal stromal tumors populations.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences Reports Progress in Clinical Trials and Financial Standing
- Cogent Biosciences reports Q3 EPS (64c), consensus (57c)
- COGT Upcoming Earnings Report: What to Expect?
- Cogent selloff on ‘old news’ is ‘unwarranted,’ says Citi
- Cogent data has positive read-through to Blueprint, says Barclays